Coherus BioSciences (CHRS) Misses Q4 EPS by 19c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.42 +7.58%
Financial Fact:
Income tax provision/(benefit): 6.81M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Income tax provision/(benefit): 6.81M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of $0.53, $0.19 worse than the analyst estimate of $0.72. Revenue for the quarter came in at $123.9 million versus the consensus estimate of $123.01 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Arena Group to rename as Paradium.AI, ticker changing to PAAI
- Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
